| Detailed information |
|---|
| CancerLivER ID | 2583 |
| Biomarker | SNRPB, TBCE, DRAP1, UFD1L, MT4, ATP6V1E, calmodulin dependent protein kinase 2, ZFP103, ATOX1, Interleukin enhancer binding factor 2 |
| Biomarker Name/Symbol (given in Publication) | Small nuclear ribonucleoprotein polypeptides B and B1 or SNRPB, Tubulin-specific chaperone e or TBCE, DR1-associated protein 1 or DRAP1, Ubiquitin fusion degradation 1-like or UFD1L, Golgi autoantigen, Metallothionein IV or MT4, Immunoglobulin superfamily, aTX1 antioxidant protein 1 homolog (yeast) or ATP6V1E, Calcium/calmodulin-dependent protein kinase 2, Zinc finger protein 103 homolog (mouse) or ZFP103, ATX1 antioxidant protein 1 homolog (yeast) or ATOX1, Interleukin enhancer binding factor 2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in G1 than L1 (with fisher ratio more than 9) |
| Level of significance | P = 0.001 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | induces apoptosis of some types of cancer cells, and IGFBP4 acts as an inhibitor of IGF-in- duced cell proliferation. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |